CSIMarket
 


Aim Immunotech Inc   (AIM)
Other Ticker:  
 
 

AIM's Operating Income Growth by Quarter and Year

Aim Immunotech Inc 's Operating Income results by quarter and year




AIM Operating Income (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - -5.56 -10.56 0.77
III Quarter September -8.16 -6.52 -3.93 -0.16
II Quarter June -5.46 -4.70 -3.72 0.72
I Quarter March -4.30 -3.15 -0.63 0.00
FY   -17.92 -19.93 -18.84 1.33



AIM Operating Income third quarter 2022 Y/Y Growth Comment
Aim Immunotech Inc in the third quarter 2022 recorded Operating Loss of $ -8.16 millions.

According to the results reported in the third quarter 2022, Aim Immunotech Inc achieved the best Operating Income growth in Biotechnology & Pharmaceuticals industry. While Aim Immunotech Inc ' s Operating Income no change of % ranks overall at the positon no. in the third quarter 2022.

Explain Operating Income growth


AIM Operating Income ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Aim Immunotech Inc 's third quarter 2022 Operating Income $ -8.16 millions AIM's Income Statement
Aim Immunotech Inc 's third quarter 2021 Operating Income $ -6.52 millions Quarterly AIM's Income Statement
New: More AIM's historic Operating Income Growth >>


AIM Operating Income (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Operating Income third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Operating Income third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Operating Income by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Aim Immunotech Inc 's Q/Q Operating Income Growth


Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


AIM's III. Quarter Q/Q Operating Income Comment
Current accomplishment of -8.16 millions by Aim Immunotech Inc look even less good if you take a look at Operating Loss -5.46 millions in the second quarter.

Within Biotechnology & Pharmaceuticals industry Aim Immunotech Inc achieved highest sequential Operating Income growth. While Aim Immunotech Inc 's Operating Income growth quarter on quarter, overall rank is .


Operating Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


AIM's III. Quarter Q/Q Operating Income Comment
III. Quarter 2022 accomplishment of -8.16 millions by Aim Immunotech Inc come out even more unfavourable considering the Operating Loss -5.46 millions in the previous quarter.

Within Biotechnology & Pharmaceuticals industry Aim Immunotech Inc achieved highest sequential Operating Income growth. While Aim Immunotech Inc 's Operating Income growth quarter on quarter, overall rank is .


Aim Immunotech Inc 's 12 Months Operating Income Growth Year on Year


Operating Income TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Operating Income 12 Months Ending $ -23.47 $ -20.97 $ -18.66 $ -19.92 $ -24.93
Y / Y Operating Income Growth (TTM) - - - - -
Year on Year Operating Income Growth Overall Ranking # # # # #
Seqeuential Operating Income Change (TTM) - - - - -
Seq. Operating Income Growth (TTM) Overall Ranking # # # # #




Cumulative Operating Income growth Comment


Aim Immunotech Inc achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Operating Income growth Comment


Aim Immunotech Inc achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Operating Income Growth
Biotechnology & Pharmaceuticals Industry Operating Income Growth Trends and Statistics
Healthcare Sector Operating Income Growth Statistics
Operating Income Growth Trends for overall market
AIM's Operating Income Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Operating Income Growth
Lowest Ranking Operating Income Growth
Operating Income Growth for AIM's Competitors
Operating Income Growth for Aim Immunotech Inc 's Suppliers
Operating Income Growth for AIM's Customers

You may also want to know
AIM's Annual Growth Rates AIM's Profitability Ratios AIM's Asset Turnover Ratio AIM's Dividend Growth
AIM's Roe AIM's Valuation Ratios AIM's Financial Strength Ratios AIM's Dividend Payout Ratio
AIM's Roa AIM's Inventory Turnover Ratio AIM's Growth Rates AIM's Dividend Comparisons



Companies with similar Operating Income no change for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Operating Income for the quarter ending Sep 30 2023
Merck and Co Inc 43.22%$ 43.220 millions
Iradimed Corporation42.91%$ 42.907 millions
Select Medical Holdings Corp42.08%$ 42.084 millions
Semler Scientific Inc 41.01%$ 41.012 millions
Dexcom Inc 39.32%$ 39.322 millions
Ir med Inc 36.64%$ 36.644 millions
Option Care Health Inc 33.48%$ 33.481 millions
Lftd Partners Inc 33.17%$ 33.168 millions
Lantheus Holdings Inc 31.04%$ 31.044 millions
Addus Homecare Corporation30.39%$ 30.389 millions
Third Harmonic Bio Inc 26.30%$ 26.304 millions
Becton Dickinson And Company25.54%$ 25.540 millions
Conmed Corporation24.96%$ 24.959 millions
Sotera Health Company20.42%$ 20.418 millions
Biomx Inc 19.03%$ 19.026 millions
Shockwave Medical Inc 18.66%$ 18.660 millions
Intuitive Surgical Inc 16.77%$ 16.771 millions
Nature s Sunshine Products inc 16.36%$ 16.361 millions
Align Technology inc 15.79%$ 15.795 millions
Stryker Corp15.22%$ 15.223 millions
Encompass Health Corporation14.02%$ 14.021 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com